Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
出版年份 2014 全文链接
标题
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 1, Pages 52-60
出版商
Springer Nature
发表日期
2014-12-03
DOI
10.1038/bjc.2014.563
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Metronomic therapy and breast cancer: A systematic review
- (2014) Emilia Montagna et al. CANCER TREATMENT REVIEWS
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
- (2013) L. S. Schwartzberg et al. CLINICAL CANCER RESEARCH
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
- (2012) William J. Gradishar et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer
- (2011) P. Gomez et al. ONCOLOGIST
- Synergistic activity of letrozole and sorafenib on breast cancer cells
- (2010) Mara A. Bonelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
- (2010) Claudine Isaacs et al. BREAST CANCER RESEARCH AND TREATMENT
- Sorafenib: a clinical and pharmacologic review
- (2010) Renuka Iyer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
- (2009) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
- (2008) S. X. Yang et al. CLINICAL CANCER RESEARCH
- Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
- (2008) D. Generali et al. CLINICAL CANCER RESEARCH
- Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
- (2008) Daniele Generali et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line
- (2007) R. N. Keswani et al. DISEASES OF THE ESOPHAGUS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started